DOI:
10.1055/s-00000019
Fortschritte der Neurologie · Psychiatrie
LinksClose Window
References
Lannfelt L, Blennow K, Zetterberg H. et al.
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lancet Neurol 2008; 7: 779-786
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.